Physician profile
Bruce K Jackson
NPI 1609883438
$3,138.77
in general payments reported to CMS, 2019-2025
25 companies · $1,228 in 2025
The $1,228 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $68.70 · 2021: $133 · 2022: $197 · 2023: $573 · 2024: $728 · 2025: $1,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,528.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $683.57 | 2022-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $528.78 | 2022-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $269.89 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $249.03 | 2019-2024 | Xarelto |
| Pfizer INC. | $190.14 | 2019-2025 | |
| Scpharmaceuticals INC. | $164.40 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.26 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $113.71 | 2023-2025 | Verquvo |
| Boston Scientific Corporation | $89.01 | 2024-2025 | Watchman Flx |
| Abiomed | $79.57 | 2024 | Impella |
| Bridgebio Pharma, INC. | $73.63 | 2025 | Attruby |
| Ge Healthcare | $66.87 | 2021-2023 | |
| Amgen INC. | $65.82 | 2024-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $65.33 | 2024-2025 | Farxiga, Brilinta, Wainua |
| Lantheus Medical Imaging, INC. | $63.74 | 2021-2023 | Definity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $58.74 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $44.16 | 2019-2024 | Evkeeza |
| Esperion Therapeutics, INC. | $37.29 | 2025 | Nexletol |
| Ionis Pharmaceuticals, INC. | $30.66 | 2025 | Tryngolza |
| Glaxosmithkline, LLC. | $29.12 | 2025 | Shingrix, Arexvy |
| Abbvie INC. | $26.43 | 2022 | |
| Astellas Pharma US INC | $23.03 | 2019 | |
| Philips North America LLC | $20.00 | 2020 | |
| Abbott Laboratories | $19.59 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.